Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tempstaff, IUK to Form PV Management Joint Venture in May
March 30, 2012
- Astellas, Pfizer Extend Lipitor Licensing Term
March 30, 2012
- Daiichi Sankyo Enters Research Collaboration Agreement on Diabetes Therapy with US Venture Company
March 30, 2012
- Otsuka Chemical to Split Up Glycotechnology Laboratory to Make It New Company
March 30, 2012
- More Than 70% of Doctors Say “Frequency of Meetings Will Not Change” Despite Review of Entertainment: CareNet Survey
March 29, 2012
- Takeda’s Novel Renal Anemia Drug Omontys Approved in the US
March 29, 2012
- Astellas Files MAA for Fixed-Dose Combination of Vesicare/Harnal in Europe
March 29, 2012
- Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
- No Change in Wholesalers’ Business Entertaining Rules for Time Being; Status of MSs with MR Qualification Remains Unclear
March 29, 2012
- Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
- Nippon Shinyaku Submits NDA for Alcohol Abstinence Aid Acamprosate
March 28, 2012
- Ajinomoto, Takeda Submit Domestic Application for Once-Monthly Risedronate
March 28, 2012
- Anticancer Agents Set to Become Top Therapeutic Category in 2012: IMS Japan
March 28, 2012
- Nichi-Iko Provides Wholesalers with Monthly Supply Volume of Epadel Generic
March 27, 2012
- Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
- Daiichi Sankyo Submits NDA for Denosumab for Osteoporosis in Japan
March 26, 2012
- Daiichi Sankyo to Develop Unapproved Narcotic Analgesic in Japan
March 26, 2012
- Suzuken Establishes New Company Specializing in Rare Diseases
March 26, 2012
- Nexium No. 1 in MR Call Frequency in HP Market in February: Rep Track Survey
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…